| Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. | |
| | |
MedLine Citation:
|
PMID: 16952975 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Electrocardiographic left ventricular hypertrophy (ECG LVH) is a powerful independent predictor of cardiovascular morbidity and mortality in hypertension. OBJECTIVE: To determine the contemporary prevalence and prognostic implications of ECG LVH in a broad spectrum of patients with heart failure with and without reduced left ventricular ejection fraction (LVEF). METHODS AND OUTCOME: The Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme randomised 7599 patients with symptomatic heart failure to receive candesartan or placebo. The primary outcome comprised cardiovascular death or hospital admission for worsening heart failure. The relative risk (RR) conveyed by ECG LVH compared with a normal ECG was examined in a Cox model, adjusting for as many as 31 covariates of prognostic importance. RESULTS: The prevalence of ECG LVH was similar in all three CHARM trials (Alternative, 15.4%; Added, 17.1%; Preserved, 14.7%; Overall, 15.7%) despite a more frequent history of hypertension in CHARM-Preserved. ECG LVH was an independent predictor of worse prognosis in CHARM-Overall. RR for the primary outcome was 1.27 (95% confidence interval (CI) 1.04 to 1.55, p = 0.018). The risk of secondary end points was also increased: cardiovascular death, 1.50 (95% CI 1.13 to 1.99, p = 0.005); hospitalisation due to heart failure, 1.19 (95% CI 0.94 to 1.50, p = 0.148); and composite major cardiovascular events, 1.35 (95% CI 1.12 to 1.62, p = 0.002). CONCLUSION: ECG LVH is similarly prevalent in patients with symptomatic heart failure regardless of LVEF. The simple clinical finding of ECG LVH was an independent predictor of a worse clinical outcome in a broad spectrum of patients with heart failure receiving extensive contemporary treatment. Candesartan had similar benefits in patients with and without ECG LVH. |
| | |
Authors:
|
N M Hawkins; D Wang; J J V McMurray; M A Pfeffer; K Swedberg; C B Granger; S Yusuf; S J Pocock; J Ostergren; E L Michelson; F G Dunn; |
Related Documents
:
|
20107905 - Body size adjustments for left ventricular mass by cardiovascular magnetic resonance an... 11153025 - Positional localization: three-dimensional transthoracic echocardiographic techniques f... 20176985 - Ethnic differences in physiological cardiac adaptation to intense physical exercise in ... 12210125 - Myocyte ploidy in heart chambers of birds with different locomotor activity. 8125425 - Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitor... 14636085 - Levosimendan: a review of its use in the management of acute decompensated heart failure. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2006-09-04 |
Journal Detail:
|
Title: Heart (British Cardiac Society) Volume: 93 ISSN: 1468-201X ISO Abbreviation: Heart Publication Date: 2007 Jan |
Date Detail:
|
Created Date: 2006-12-15 Completed Date: 2007-01-24 Revised Date: 2010-09-14 |
Medline Journal Info:
|
Nlm Unique ID: 9602087 Medline TA: Heart Country: England |
Other Details:
|
Languages: eng Pagination: 59-64 Citation Subset: AIM; IM |
Affiliation:
|
Department of Cardiology, Stobhill Hospital, Balornock Road, Springburn, Glasgow G21 3UW, UK. nathawkins@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angiotensin II Type 1 Receptor Blockers / therapeutic use Antihypertensive Agents / therapeutic use Benzimidazoles / therapeutic use Electrocardiography Epidemiologic Methods Female Heart Failure / drug therapy, epidemiology, etiology* Hospitalization / statistics & numerical data Humans Hypertrophy, Left Ventricular / complications*, epidemiology, physiopathology Male Middle Aged Prognosis Severity of Illness Index Stroke Volume Tetrazoles / therapeutic use Treatment Outcome Ventricular Dysfunction, Left / etiology |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Tetrazoles; 139481-59-7/candesartan |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an i...
Next Document: Relation between renal function within the normal range and central and peripheral arterial stiffnes...